nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—IL1B—Serotonin Transporter Activity—TPH2—attention deficit hyperactivity disorder	0.0294	0.0547	CbGpPWpGaD
Minocycline—CASP1—forebrain—attention deficit hyperactivity disorder	0.025	0.0538	CbGeAlD
Minocycline—CYCS—forebrain—attention deficit hyperactivity disorder	0.024	0.0518	CbGeAlD
Minocycline—IL1B—Serotonin Transporter Activity—SLC6A4—attention deficit hyperactivity disorder	0.0235	0.0438	CbGpPWpGaD
Minocycline—CASP1—cardiovascular system—attention deficit hyperactivity disorder	0.0211	0.0455	CbGeAlD
Minocycline—CASP3—forebrain—attention deficit hyperactivity disorder	0.0206	0.0444	CbGeAlD
Minocycline—CYCS—cardiovascular system—attention deficit hyperactivity disorder	0.0203	0.0438	CbGeAlD
Minocycline—CASP1—Parkin-Ubiquitin Proteasomal System pathway—STUB1—attention deficit hyperactivity disorder	0.018	0.0336	CbGpPWpGaD
Minocycline—IL1B—Serotonin Transporter Activity—MAOA—attention deficit hyperactivity disorder	0.0177	0.0329	CbGpPWpGaD
Minocycline—CASP3—cardiovascular system—attention deficit hyperactivity disorder	0.0174	0.0375	CbGeAlD
Minocycline—CASP1—midbrain—attention deficit hyperactivity disorder	0.0165	0.0356	CbGeAlD
Minocycline—IL1B—forebrain—attention deficit hyperactivity disorder	0.0164	0.0355	CbGeAlD
Minocycline—CYCS—midbrain—attention deficit hyperactivity disorder	0.0159	0.0342	CbGeAlD
Minocycline—MMP9—Matrix Metalloproteinases—MMP16—attention deficit hyperactivity disorder	0.0157	0.0292	CbGpPWpGaD
Minocycline—MMP9—Activation of Matrix Metalloproteinases—MMP16—attention deficit hyperactivity disorder	0.0149	0.0277	CbGpPWpGaD
Minocycline—IL1B—cardiovascular system—attention deficit hyperactivity disorder	0.0139	0.03	CbGeAlD
Minocycline—CASP1—nervous system—attention deficit hyperactivity disorder	0.0135	0.0292	CbGeAlD
Minocycline—CASP1—central nervous system—attention deficit hyperactivity disorder	0.013	0.0281	CbGeAlD
Minocycline—CYCS—nervous system—attention deficit hyperactivity disorder	0.013	0.0281	CbGeAlD
Minocycline—CYCS—Orphan transporters—GABRQ—attention deficit hyperactivity disorder	0.013	0.0243	CbGpPWpGaD
Minocycline—CYCS—p75(NTR)-mediated signaling—RTN4—attention deficit hyperactivity disorder	0.0129	0.024	CbGpPWpGaD
Minocycline—CASP1—cerebellum—attention deficit hyperactivity disorder	0.0127	0.0275	CbGeAlD
Minocycline—CYCS—central nervous system—attention deficit hyperactivity disorder	0.0126	0.0271	CbGeAlD
Minocycline—IL1B—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.0125	0.0233	CbGpPWpGaD
Minocycline—IL1B—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.0123	0.0229	CbGpPWpGaD
Minocycline—CYCS—cerebellum—attention deficit hyperactivity disorder	0.0123	0.0265	CbGeAlD
Minocycline—MMP9—cardiovascular system—attention deficit hyperactivity disorder	0.0116	0.025	CbGeAlD
Minocycline—CASP3—nervous system—attention deficit hyperactivity disorder	0.0112	0.0241	CbGeAlD
Minocycline—IL1B—midbrain—attention deficit hyperactivity disorder	0.0109	0.0234	CbGeAlD
Minocycline—CASP3—central nervous system—attention deficit hyperactivity disorder	0.0108	0.0232	CbGeAlD
Minocycline—CYCS—Parkinsons Disease Pathway—SLC6A3—attention deficit hyperactivity disorder	0.0106	0.0198	CbGpPWpGaD
Minocycline—CASP3—cerebellum—attention deficit hyperactivity disorder	0.0105	0.0227	CbGeAlD
Minocycline—CASP3—p75(NTR)-mediated signaling—RTN4—attention deficit hyperactivity disorder	0.0104	0.0194	CbGpPWpGaD
Minocycline—CASP1—brain—attention deficit hyperactivity disorder	0.0104	0.0223	CbGeAlD
Minocycline—IL1B—Monoamine Transport—SLC6A4—attention deficit hyperactivity disorder	0.00999	0.0186	CbGpPWpGaD
Minocycline—CYCS—brain—attention deficit hyperactivity disorder	0.00997	0.0215	CbGeAlD
Minocycline—CASP3—Degradation of the extracellular matrix—MMP16—attention deficit hyperactivity disorder	0.00945	0.0176	CbGpPWpGaD
Minocycline—ALOX5—cardiovascular system—attention deficit hyperactivity disorder	0.00916	0.0198	CbGeAlD
Minocycline—CASP3—p75 NTR receptor-mediated signalling—RTN4—attention deficit hyperactivity disorder	0.00905	0.0169	CbGpPWpGaD
Minocycline—IL1B—nervous system—attention deficit hyperactivity disorder	0.00892	0.0193	CbGeAlD
Minocycline—IL1B—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.00891	0.0166	CbGpPWpGaD
Minocycline—IL1B—central nervous system—attention deficit hyperactivity disorder	0.00859	0.0185	CbGeAlD
Minocycline—CASP3—Parkinsons Disease Pathway—SLC6A3—attention deficit hyperactivity disorder	0.00858	0.016	CbGpPWpGaD
Minocycline—CASP3—brain—attention deficit hyperactivity disorder	0.00854	0.0184	CbGeAlD
Minocycline—VEGFA—cerebellum—attention deficit hyperactivity disorder	0.00826	0.0178	CbGeAlD
Minocycline—SLC22A7—Fluoropyrimidine Activity—DPYD—attention deficit hyperactivity disorder	0.00773	0.0144	CbGpPWpGaD
Minocycline—CYCS—Alzheimers Disease—CACNA1C—attention deficit hyperactivity disorder	0.0076	0.0142	CbGpPWpGaD
Minocycline—MMP9—nervous system—attention deficit hyperactivity disorder	0.00744	0.016	CbGeAlD
Minocycline—MMP9—central nervous system—attention deficit hyperactivity disorder	0.00716	0.0154	CbGeAlD
Minocycline—IL1B—brain—attention deficit hyperactivity disorder	0.00682	0.0147	CbGeAlD
Minocycline—CASP3—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.00677	0.0126	CbGpPWpGaD
Minocycline—VEGFA—brain—attention deficit hyperactivity disorder	0.00671	0.0145	CbGeAlD
Minocycline—MMP9—Degradation of the extracellular matrix—MMP16—attention deficit hyperactivity disorder	0.00656	0.0122	CbGpPWpGaD
Minocycline—CASP3—Alzheimers Disease—CACNA1C—attention deficit hyperactivity disorder	0.00613	0.0114	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.00612	0.0114	CbGpPWpGaD
Minocycline—VEGFA—Regulation of gene expression by Hypoxia-inducible Factor—EP300—attention deficit hyperactivity disorder	0.00596	0.0111	CbGpPWpGaD
Minocycline—ALOX5—nervous system—attention deficit hyperactivity disorder	0.00588	0.0127	CbGeAlD
Minocycline—CASP3—Posttranslational regulation of adherens junction stability and dissassembly—BDNF—attention deficit hyperactivity disorder	0.00579	0.0108	CbGpPWpGaD
Minocycline—MMP9—brain—attention deficit hyperactivity disorder	0.00568	0.0123	CbGeAlD
Minocycline—ALOX5—central nervous system—attention deficit hyperactivity disorder	0.00566	0.0122	CbGeAlD
Minocycline—IL1B—Alzheimers Disease—CACNA1C—attention deficit hyperactivity disorder	0.00555	0.0103	CbGpPWpGaD
Minocycline—ALOX5—cerebellum—attention deficit hyperactivity disorder	0.00553	0.0119	CbGeAlD
Minocycline—CYCS—p75(NTR)-mediated signaling—BDNF—attention deficit hyperactivity disorder	0.00537	0.01	CbGpPWpGaD
Minocycline—SLC22A7—brain—attention deficit hyperactivity disorder	0.00526	0.0113	CbGeAlD
Minocycline—SLC22A6—brain—attention deficit hyperactivity disorder	0.00508	0.011	CbGeAlD
Minocycline—MMP9—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.0047	0.00875	CbGpPWpGaD
Minocycline—ALOX5—brain—attention deficit hyperactivity disorder	0.00449	0.0097	CbGeAlD
Minocycline—CASP3—p75(NTR)-mediated signaling—BDNF—attention deficit hyperactivity disorder	0.00433	0.00808	CbGpPWpGaD
Minocycline—CASP1—IFN-gamma pathway—EP300—attention deficit hyperactivity disorder	0.0041	0.00764	CbGpPWpGaD
Minocycline—SLC22A8—nervous system—attention deficit hyperactivity disorder	0.00398	0.00858	CbGeAlD
Minocycline—CASP3—Extracellular matrix organization—MMP16—attention deficit hyperactivity disorder	0.00396	0.00738	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00389	0.00725	CbGpPWpGaD
Minocycline—SLC22A8—central nervous system—attention deficit hyperactivity disorder	0.00383	0.00826	CbGeAlD
Minocycline—IL1B—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00352	0.00656	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00344	0.00642	CbGpPWpGaD
Minocycline—SLC22A11—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.0034	0.00634	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00334	0.00623	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00333	0.00621	CbGpPWpGaD
Minocycline—CYCS—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00333	0.00621	CbGpPWpGaD
Minocycline—CYCS—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00318	0.00592	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00311	0.00579	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00311	0.00579	CbGpPWpGaD
Minocycline—SLC22A7—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00309	0.00575	CbGpPWpGaD
Minocycline—CASP1—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00308	0.00574	CbGpPWpGaD
Minocycline—SLC22A8—brain—attention deficit hyperactivity disorder	0.00304	0.00656	CbGeAlD
Minocycline—IL1B—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00303	0.00564	CbGpPWpGaD
Minocycline—VEGFA—SHP2 signaling—BDNF—attention deficit hyperactivity disorder	0.003	0.00559	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00282	0.00526	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00281	0.00524	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00281	0.00524	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—MMP16—attention deficit hyperactivity disorder	0.00275	0.00513	CbGpPWpGaD
Minocycline—VEGFA—Cellular response to hypoxia—EP300—attention deficit hyperactivity disorder	0.00263	0.00491	CbGpPWpGaD
Minocycline—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.0026	0.00485	CbGpPWpGaD
Minocycline—SLC22A8—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00259	0.00483	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.00257	0.00479	CbGpPWpGaD
Minocycline—IL1B—IFN-gamma pathway—EP300—attention deficit hyperactivity disorder	0.00256	0.00478	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00255	0.00476	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00253	0.00471	CbGpPWpGaD
Minocycline—IL1B—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00243	0.00453	CbGpPWpGaD
Minocycline—CASP3—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00241	0.00448	CbGpPWpGaD
Minocycline—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.00236	0.0044	CbGpPWpGaD
Minocycline—CASP3—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—attention deficit hyperactivity disorder	0.00236	0.0044	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00234	0.00437	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00234	0.00436	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00226	0.00421	CbGpPWpGaD
Minocycline—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—EP300—attention deficit hyperactivity disorder	0.00222	0.00413	CbGpPWpGaD
Minocycline—SLC22A6—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00216	0.00403	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00213	0.00398	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00213	0.00396	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00212	0.00395	CbGpPWpGaD
Minocycline—VEGFA—HIF-2-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00206	0.00384	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00204	0.00381	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00201	0.00376	CbGpPWpGaD
Minocycline—CASP1—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00201	0.00374	CbGpPWpGaD
Minocycline—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.00199	0.0037	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00196	0.00365	CbGpPWpGaD
Minocycline—CASP1—Immune System—STUB1—attention deficit hyperactivity disorder	0.00194	0.00362	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00193	0.00359	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00192	0.00358	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00191	0.00355	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00187	0.00349	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00187	0.00349	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00185	0.00345	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00173	0.00322	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00173	0.00322	CbGpPWpGaD
Minocycline—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.00166	0.00309	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00165	0.00307	CbGpPWpGaD
Minocycline—VEGFA—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00162	0.00301	CbGpPWpGaD
Minocycline—CASP1—Direct p53 effectors—EP300—attention deficit hyperactivity disorder	0.0016	0.00297	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00157	0.00292	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00152	0.00284	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.0015	0.0028	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.0015	0.00279	CbGpPWpGaD
Minocycline—CASP1—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00147	0.00274	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00141	0.00263	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.00138	0.00256	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00136	0.00253	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00135	0.00252	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00133	0.00248	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00132	0.00247	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00132	0.00246	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00132	0.00246	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.00131	0.00243	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00126	0.00234	CbGpPWpGaD
Minocycline—IL1B—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00125	0.00234	CbGpPWpGaD
Minocycline—IL1B—Immune System—STUB1—attention deficit hyperactivity disorder	0.00121	0.00226	CbGpPWpGaD
Minocycline—VEGFA—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00121	0.00226	CbGpPWpGaD
Minocycline—MMP9—Validated targets of C-MYC transcriptional activation—EP300—attention deficit hyperactivity disorder	0.00121	0.00225	CbGpPWpGaD
Minocycline—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—attention deficit hyperactivity disorder	0.0012	0.00223	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.00119	0.00223	CbGpPWpGaD
Minocycline—SLC22A11—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00118	0.00221	CbGpPWpGaD
Minocycline—CYCS—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00116	0.00216	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00116	0.00216	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00115	0.00214	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00111	0.00207	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.0011	0.00206	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.0011	0.00205	CbGpPWpGaD
Minocycline—SLC22A7—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00107	0.002	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00107	0.002	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00105	0.00196	CbGpPWpGaD
Minocycline—CASP3—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00104	0.00193	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00101	0.00188	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000982	0.00183	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.000932	0.00174	CbGpPWpGaD
Minocycline—IL1B—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00092	0.00171	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000914	0.0017	CbGpPWpGaD
Minocycline—SLC22A8—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000903	0.00168	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000867	0.00162	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000859	0.0016	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000852	0.00159	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000822	0.00153	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000771	0.00144	CbGpPWpGaD
Minocycline—CYCS—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000762	0.00142	CbGpPWpGaD
Minocycline—CYCS—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000762	0.00142	CbGpPWpGaD
Minocycline—SLC22A6—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000753	0.0014	CbGpPWpGaD
Minocycline—CYCS—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00075	0.0014	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000745	0.00139	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00073	0.00136	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000716	0.00133	CbGpPWpGaD
Minocycline—CYCS—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000697	0.0013	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000696	0.0013	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00068	0.00127	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000669	0.00125	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000625	0.00116	CbGpPWpGaD
Minocycline—CYCS—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000609	0.00114	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000609	0.00113	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000602	0.00112	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000601	0.00112	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00058	0.00108	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000546	0.00102	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000523	0.000974	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000518	0.000965	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000517	0.000964	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000514	0.000958	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000507	0.000944	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000506	0.000943	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000497	0.000926	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00047	0.000875	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00047	0.000875	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000462	0.000861	CbGpPWpGaD
Minocycline—CYCS—Metabolism—COMT—attention deficit hyperactivity disorder	0.000462	0.000861	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000459	0.000855	CbGpPWpGaD
Minocycline—CYCS—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000459	0.000855	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000449	0.000837	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000442	0.000824	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00044	0.00082	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000431	0.000804	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00043	0.000801	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000411	0.000766	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.0004	0.000745	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000398	0.000742	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000391	0.000729	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000387	0.00072	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000383	0.000713	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000375	0.0007	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00036	0.000671	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000357	0.000666	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000351	0.000655	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000307	0.000572	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000305	0.000568	CbGpPWpGaD
Minocycline—CASP1—Immune System—EP300—attention deficit hyperactivity disorder	0.000299	0.000558	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000285	0.000532	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—COMT—attention deficit hyperactivity disorder	0.000285	0.00053	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000283	0.000527	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000279	0.00052	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000276	0.000515	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000274	0.000511	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000272	0.000506	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000268	0.0005	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000266	0.000497	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000252	0.00047	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00025	0.000466	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000248	0.000462	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000242	0.000451	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00024	0.000447	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000237	0.000443	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000236	0.00044	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000233	0.000434	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000217	0.000404	CbGpPWpGaD
Minocycline—CYCS—Metabolism—EP300—attention deficit hyperactivity disorder	0.000198	0.000369	CbGpPWpGaD
Minocycline—IL1B—Immune System—EP300—attention deficit hyperactivity disorder	0.000187	0.000349	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000175	0.000326	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000152	0.000283	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000134	0.000249	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—EP300—attention deficit hyperactivity disorder	0.000122	0.000227	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.28e-05	0.000173	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.05e-05	0.00015	CbGpPWpGaD
